The markets opened mixed with the Dow losing 23 points to 20,644 over concerns about economic growth prospects. Nasdaq rose 9 points to 5,803.
On the upside
The Food and Drug Administration granted Orphan Drug Designation to Moleculin Biotech's (Nasdaq: MBRX) acute myeloid leukemia treatment Annamycin.
Drexel Hamilton analyst Brian White initiated coverage of Snap (NYSE: SNAP) with a Buy rating and a $30 price target.
Duluth Holdings (Nasdaq: DLTH) reported better than expected earnings for the fourth quarter.
On the downside
Sears Holdings (Nasdaq: SHLD) warned that it had substantial doubt about its ability to continue operations.
Diana Containerships (Nasdaq: DCIX) entered into a Securities Purchase Agreement with Kalani Investments.
Regenxbio (Nasdaq: RGNX) priced its secondary offering of 3.7 million common shares at the discounted price of $20.50 per share.
In the broad market, declining issues outpaced advancers by a margin of more than 2 to 1 on both the NYSE and on Nasdaq. The broader S&P 500 index eased a fraction to 2,343. Bitcoin plunged $93 to $1,029.